full an Thanks, for this of today. fourth XXXX our call, share to morning, results thank recent update provide year on and for a On joining activities. we'll quarter and and Alex. everyone Good us the you range
in office team there a percentage we on bioformatics will and growing I'll University the of largest software positions. where The Diego, some pharmaceutical hubs the our Eventually, Bay have one as instrument with in and our of teams engineering to the focus office development, and in San of The biotechnology you an be commercial work the based most now sharing and the Center, progress today new is we've and extraordinary country. due well. Town being talent-rich in Area engineering, anticipate opened reagent Seattle initially
these the of and Nautilus by of to focus milestones ever remain longer-term other and world. lives Through motivated the Proteomics the on and reflects efforts, our our expansion and name This in commercialization improving geographic around development health short-term people goals. we of footprint goal the continued of progress millions revolutionize
Our goal, it fully to this this to what goal committed doing takes entire reality. make motivated team aligned a is by and
on mid-XXXX. it of and our towards to a see as will reflect our move instruments and XXXX, that I XXXX progress. launch fruit When Progress I year as platform, reagents accomplishment proteome a in foundational bear and analysis through we plan
progress core are goals Here a solid examples. in made We scientific against our few XXXX.
reagents R&D Affinity scale addition the and with of Reagent development VP XXXX Ken in move in Sherry development towards our commercialization. team advances readiness activities customer Development leadership robustness Wilcox Development. the were offering. Our major helped Platform of and as focus pay the dividends advancing has and as build the our our continue of world-class XXXX of out Reagent to Ken Critical strengthen progress our of increasing us Kun such to a hand-in-hand consumables, cells. we year was will core This and which on team, Cherry as quality to as of last goes VP and both and with efforts those blood
diverse to are last closely on XXXX with year this progress to that process collaborations the phases involves teams. regard. of I concept taking focus important pleased The commercial our of instrument also instrument. commercial saw I'm number from advancing saw continued a build orchestrated an between in use
the all the elements we to of Throughout accelerate transition platform manufacturing commercial organization, work That successfully XXXX. and a continue posture we will entire availability. build across towards R&D as continues to in
seeing the and quality partnerships. results would resources capital-efficient from became compared were our external in of the probe efforts internal we to those they to with sought underperforming clear that we development partnerships our we yield put were made XXXX, in to the most internal decision Early own volume our where manner. some When it of efforts, augment probes
Our last year teams binders to are that affinity able internal to are a internal reagent across epitope demonstrated development throughout that at we of conferences pipeline generate probes our Data proceed targets. short extremely continues well. strong range shared
and in wide-ranging coupled increase transitions These experimental improvements, on-platform workflow, allowed scale. radically advances our us with have our to
are was only experiments on to Our cycles. demonstrated internal scale, not experiments but to execute performing target for at of experiments this We've to scale. XX we XXXX able now up routinely this be
The raging deposition platform, approach. to posters our covering present our X December, Congress all from the early progress achieved aspects us to enabled Affinity development throughout ranging in of XXXX at HUPO molecule World single
these of posters in XX across that results experiment computational experimental an integration the of demonstrated probes of These XX of model a decoding cycles. multi-affinity confidence our were demonstrated our these and XXXX. results building end-to-end One expand to on protein continue data look workflows. and in full forward exciting to we This from science,
accomplishments global as excited future. and our in the portfolio patents XXXX far. doubled protection filed remain seek and reach patent patent in in foreign over commercialize we to and XX XXXX, forward, thus make going U.S. expect a U.S. in platform. our markets me families granted and many we U.S. XXXX These with pending will the we of Also nearly total In in our in abroad to for other XX where IP strategy our
my much in continue work While that will that efforts remains beyond. other to and we XXXX be to pay foundational done, I'm recognize belief these and off firm in
QX, a at we areas explore the broad Nautilus revolutionizing enable of spectrum designed mind of us from researchers massive uncover on announced proteome others scale. Challenge, goal biological to part important new join to in of An this disciplines to was Access a it contest and calling the First is inspiring we're And in journey. that what insights Proteomics that with new
to announce the of of emerging them traditional to and their demand the The response early review submissions type we HUPO limitations excited been the the chance winners explore proposals we methods. tuned hope methods globe We're It unbounded on more when across unlocked access peptide and March. rewarding. the the comprehensive proteome for deadline the by we affinity-based of near incredibly has see both Stay has from and for sequencing researchers in samples, the very creativity it the will to offered how at revealed has passed, challenge The Conference pent-up U.S. we've very first in received. for XXXX and future has inherent coverage.
are by Nautilus specific intrinsic with studying and in institute, a glioma, utility the genomics joining announced to Genentech, Anderson partners a Our research to Amgen on pontine the new and existing targets childhood proteomics. us fatal often also Recently, translational diffuse collaborations revolutionize with explore protein represent journey the epigenetic our partnership who protein MD platform DIPG, of to cancer. the at by this goal we expectation when Work kick detect the proteiform DIPG of The work will peptide-based and findings in Proteiform its a should better that to is team partnership of by early landscape not interrogating level. publish mechanisms molecule is understand proteins specific analysis possible the the is single completed. off at year, methods. this rare
we interest From very use set applications across seeing by collaborators I'm about deploying TGM platform our cases. diseases, childhood and doing against. to, cancer use broad of from neurodegenerative with I'm we'll and wide be a researchers are are to the cases the spectrum especially our excited excited work of
as of participated a case team use many in ideas I sponsor -- Congress primary heard World Proteome Human mentioned earlier, we as early when Our the December. such Organizations
investigate traditional deep, ties ask of methods. Aside researchers our possible. could It was their to and to our our long-standing a the how exciting complement conversations enable with our enthusiastically valuable than hear presentations, to before with engaging to platform see serve buzzing to spectrometry, mass during many proteomic poster and researchers as platform from analysis X ever potential questions fundamentally researchers was booth PIs discussing different
enthusiastic first Conversations year, These of the solution, will that potential platform value desire at seeking market belief delivers a affinity-based with and researchers others highly and emerging to methods an extraordinary bring serve of over over one HUPO research that for a unlock platform response have limitations proposition sequencing submissions methods to Nautilus challenge overcomes a traditional the and competitive all again peptide unmatched my expressed inherent both and single of excited our our terms I'm forward partners, get to many they of as the biological to them the innovative, platform assist sensitivity, throughout and of a researchers strengthen to a strong scale our research. and to researchers that and proteome. access drive impactful moat, reproducibility. molecule wide the of into the differentiated in the their the hands
my continue and we team the financial As and to management of current discussed, gravity adapt proactively to previously economic climate. the I
us enable well runway balancing our progress that to and We will scientific to investments are our managing that resources drive tightly into forward. with XXXX our maximize
financials. Anna the for on call me our and that, let year more a at to look XXXX Anna? QX For hand over full
